{"product_id":"adpt-ansoff-analysis","title":"(ADPT) Adaptive Biotechnologies Corporation ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Adaptive Biotechnologies Corporation Ansoff Matrix Analysis helps you quickly assess the company’s growth options across market penetration, market development, product development, and diversification; the page includes a real preview\/sample so you can evaluate style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific analysis for strategy, investing, or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eclonoSEQ MRD in 3 core hematologic cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eclonoSEQ MRD can gain share in 3 core cancers: multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Because it is already a clinical test for minimal residual disease, the main growth lever is not new patient conversion but more serial testing within the same eligible base. If hematology and oncology teams move from one-off use to repeated monitoring at each response check, recurring test volume rises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCLIA-validated testing for other lymphoid cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe CLIA-validated clonoSEQ laboratory-developed test lets Adaptive Biotechnologies Corporation sell beyond its 3 named indications, so it can reach more lymphoid cancers with the same assay platform. That is a direct share-gain move inside an existing clinical base, and it matters in a U.S. hematologic cancer market with about 176,000 new lymphoma and myeloma cases each year. Adoption can rise without a new product build.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eimmunoSEQ translational research expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eimmunoSEQ is already a core tool for translational research and biomarker discovery, so market penetration means deepening use in the same life science accounts and winning repeat study work. Its edge is immune repertoire analysis, which helps teams find prognostic and diagnostic markers faster. That makes expansion more about higher sample volume and broader project use than new product fit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eT-Detect COVID repeat use for past infection confirmation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eT-Detect COVID stays focused on confirming past infection, so market penetration hinges on keeping it in clinical and research workflows that need retrospective evidence. With WHO tracking 777 million+ confirmed cases and 7 million+ deaths worldwide by 2025, the need for proof of prior infection remains real.\u003c\/p\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation can extend use without a new platform because T-Detect runs on its immune sequencing engine, which lowers adoption friction for labs already using sequencing. The main win is repeat use in cases where antibody signals fade but T-cell memory can still show prior infection.\u003c\/p\u003e\n\u003cp\u003eThat makes the product a niche, workflow-based offer, not a mass-screening test, so penetration depends on clinician trust, reimbursement, and fit in post-infection review paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets prior-infection confirmation\u003c\/li\u003e\n\u003cli\u003eUses existing immune sequencing\u003c\/li\u003e\n\u003cli\u003eFits repeat clinical and research use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eimmunoSEQ T-MAP COVID in vaccine studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eimmunoSEQ T-MAP COVID gives Adaptive Biotechnologies Corporation a clear penetration path in existing vaccine R\u0026amp;D accounts by measuring T-cell immune responses across repeat study visits. That supports deeper use inside the same programs, not just one-off tests. The fit is strong for current research customers, so sales can expand within ongoing vaccine studies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat testing drives account depth.\u003c\/li\u003e\n\u003cli\u003eProgram-level use supports stickier revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdaptive Biotech’s Growth Hinges on Repeat MRD Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s market penetration is strongest in clonoSEQ MRD, where growth comes from more serial testing in the same multiple myeloma, B-cell ALL, and CLL base. The U.S. hematologic cancer pool is about 176,000 new lymphoma and myeloma cases a year, so share gains come from repeat use, not new product change.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003ePenetration lever\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eclonoSEQ\u003c\/td\u003e\n\u003ctd\u003eMore serial MRD tests\u003c\/td\u003e\n\u003ctd\u003e176,000 new U.S. cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eT-Detect COVID\u003c\/td\u003e\n\u003ctd\u003eRepeat prior-infection use\u003c\/td\u003e\n\u003ctd\u003e777M cases, 7M deaths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Adaptive Biotechnologies Corporation’s growth strategy across products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a quick Adaptive Biotechnologies Ansoff snapshot to simplify growth decisions and reduce strategic guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, reputable sources to validate Ansoff Matrix growth paths for Adaptive Biotechnologies, enabling quick verification and defensible strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eclonoSEQ into broader lymphoid cancer segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eclonoSEQ can expand beyond its 3 core lymphoid cancer uses by moving into more B-cell and other lymphoid settings with the same CLIA-validated LDT. That makes this a market development play: one assay, more clinical segments. Adaptive reported 2025 revenue of about $177 million, with clonoSEQ still the main growth engine, so wider hematologic oncology use matters. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eimmunoSEQ into more drug discovery programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eimmunoSEQ can move from current drug discovery use into more biopharma and translational research programs by serving new customers that need deep immune profiling. The same sequencing platform can fit broader discovery workflows, which expands reach without changing the core product. This is market development: sell the existing tool to more program types and research teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eT-Detect COVID in broader infectious disease research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eT-Detect COVID already proved that Adaptive Biotechnologies Corporation can use T-cell receptor sequencing to confirm prior SARS-CoV-2 exposure, in a market tied to more than 770 million reported COVID-19 cases worldwide. \u003c\/p\u003e\n\u003cp\u003eThe market development move is to sell the same assay logic to infectious disease researchers and retrospective serology teams studying other pathogens, not just COVID-19. \u003c\/p\u003e\n\u003cp\u003eThat widens the customer base from one indication to hospitals, academic labs, and biopharma groups that need history-of-infection data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eimmunoSEQ T-MAP COVID for more vaccine developers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eimmunoSEQ T-MAP COVID is already used by vaccine developers and researchers, so market development means selling the same assay into more vaccine programs and more sponsor organizations. Adaptive Biotechnologies can widen reach without changing the product, which is a low-capex growth path for a platform built for immune-response mapping.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame assay, broader sponsor base.\u003c\/li\u003e\n\u003cli\u003eMore vaccine programs, same workflow.\u003c\/li\u003e\n\u003cli\u003eGrowth comes from customer expansion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ecommercial-stage immune medicine platform into new customer groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation can grow its commercial-stage immune medicine platform by selling deeper into life science, clinical diagnostic, and drug discovery accounts. This is market development, not a new product line, because the company is expanding the customer base for assets like clonoSEQ and its immune profiling platform. The move fits a recurring-revenue model and should lift share of wallet from existing commercial channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame platform, more customer groups\u003c\/li\u003e\n\u003cli\u003eTargets life science, diagnostics, drug discovery\u003c\/li\u003e\n\u003cli\u003eExpands the current commercial base\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdaptive Biotechnologies Expands Reach Without Changing Its Core Assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s market development is to sell clonoSEQ and immunoSEQ into more B-cell, lymphoid, infectious disease, and biopharma accounts without changing the core assays. This is a same-product, more-customer move. In 2025, Company Name reported about $177 million in revenue, so wider channel reach matters.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eclonoSEQ\u003c\/td\u003e\n\u003ctd\u003eMore lymphoid uses\u003c\/td\u003e\n\u003ctd\u003eRevenue driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eimmunoSEQ\u003c\/td\u003e\n\u003ctd\u003eMore biopharma teams\u003c\/td\u003e\n\u003ctd\u003ePlatform expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAdaptive Biotechnologies Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003epipeline clinical products for cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation is building pipeline clinical products for cancer diagnosis, monitoring, and treatment, so this is product development: new offerings for the same clinical and research customers. The pipeline can go beyond current MRD and immunosequencing tools, which keeps the company tied to its core market while broadening use cases. In 2025, this remains the key growth path for Adaptive Biotechnologies Corporation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003epipeline products for autoimmune disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation is extending its immune-sequencing platform into pipeline products for autoimmune disorders, which is a product development move in the Ansoff Matrix. This broadens the clinical portfolio beyond current immune-medicine uses while staying anchored to the same science base. It also adds a new disease area without leaving the company’s core technology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003epipeline products for infectious diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation is extending its immune-repertoire and diagnostic platform into pipeline products for infectious diseases, which makes this a clear product development move. By building on the same clinical and research base, Adaptive Biotechnologies Corporation can sell new offerings to existing customers faster and at lower launch cost. This also widens its addressable market beyond immune-oncology into diagnostics and infectious disease testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003esingle blood-sample multi-disease diagnostics with Microsoft\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s work with Microsoft is a product development move: it uses Adaptive’s immune-sequencing data and Microsoft cloud\/AI tools to build a new test that could spot multiple diseases from one blood draw. The partnership targets earlier diagnosis with fewer samples, which can lift clinical value and broaden future test demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew multi-disease diagnostic offering\u003c\/li\u003e\n\u003cli\u003eSingle blood sample, broader use case\u003c\/li\u003e\n\u003cli\u003eAdaptive data plus Microsoft AI stack\u003c\/li\u003e\n\u003cli\u003eHigher early-detection potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eneoantigen-directed T-cell therapies with Genentech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Biotechnologies and Genentech are jointly developing, manufacturing, and commercializing neoantigen-directed T-cell therapies, which is a clean product-development move in oncology. It pushes Adaptive beyond diagnostics and research tools into higher-value therapeutic products, and the collaboration fits a pipeline built for tumor-specific targets rather than broad, one-size-fits-all drugs.\u003c\/p\u003e\n\u003cp\u003eAdaptive reported FY2024 revenue of $175.8 million, so this kind of therapy partnership can matter a lot for future mix and margin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMoves Adaptive into therapeutics\u003c\/li\u003e\n\u003cli\u003eUses shared development and manufacturing\u003c\/li\u003e\n\u003cli\u003eTargets neoantigens in oncology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdaptive Biotech Expands From Diagnostics to Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s product development path is to turn its immune-sequencing base into new diagnostics and therapies for the same clinical customers. The Microsoft-backed multi-disease blood test and Genentech neoantigen T-cell therapy work both expand the portfolio without leaving the core science. FY2024 revenue was $175.8 million, so pipeline success can change the mix fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlood-test expansion\u003c\/td\u003e\n\u003ctd\u003eNew multi-disease use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eT-cell therapy\u003c\/td\u003e\n\u003ctd\u003eMoves into therapeutics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eneoantigen-directed T-cell therapy commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Genentech collaboration moves Adaptive Biotechnologies from diagnostics into cancer therapeutics, so it is a clear diversification play. It adds a new product category and a new commercial model, and it takes Adaptive deeper into the oncology value chain with neoantigen-directed T-cell therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003emulti-disease early detection from one blood sample\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Microsoft collaboration for multi-disease early detection from one blood sample is a clear diversification move: it adds a new product concept and pushes Adaptive Biotechnologies Corporation beyond immune profiling into a broader screening market. This is a different diagnostic segment, not just a line extension, so it raises both upside and execution risk. If it works, it could expand Adaptive Biotechnologies Corporation’s addressable market far beyond its current core tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eautoimmune diagnosis and treatment pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s autoimmune diagnosis and treatment pipeline is a diversification move because it goes beyond its current commercial diagnostics base into a new disease market. Autoimmune disease affects about 50 million Americans, so even a small share can be meaningful. But this path needs new clinical evidence, new reimbursement rules, and new positioning. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003einfectious disease diagnosis and treatment pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s infectious disease pipeline extends its immune-medicine platform beyond hematologic oncology and research, opening new clinical uses and broader buyer groups. That matters in a large market: the WHO estimated 10.8 million tuberculosis cases in 2023, showing how big infectious-disease demand can be. If these assets advance, they can diversify revenue away from a single end market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew use case: infectious disease diagnosis\u003c\/li\u003e\n\u003cli\u003eNew buyers: hospitals and public health labs\u003c\/li\u003e\n\u003cli\u003ePlatform reuse: immune sequencing and analysis\u003c\/li\u003e\n\u003cli\u003eMarket tailwind: 10.8 million TB cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eimmune medicine beyond current commercial products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdaptive Biotechnologies Corporation’s move into immune medicine beyond current commercial products is the clearest diversification play in its Ansoff Matrix. Its immune-mapping platform can support multi-disease screening and treatment across a wider set of markets, and management reported FY2025 revenue of about $xxx million, showing the core business still funds expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMoves from diagnosis into treatment\u003c\/li\u003e\n\u003cli\u003eExpands from one disease to many\u003c\/li\u003e\n\u003cli\u003eTargets larger, new end markets\u003c\/li\u003e\n\u003cli\u003eHighest-risk, highest-growth Ansoff route\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversification Pushes Adaptive Biotechnologies Into Bigger, Riskier Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification is Adaptive Biotechnologies Corporation’s highest-risk Ansoff move: it is shifting from immune profiling into cancer therapy, multi-disease screening, autoimmune care, and infectious disease. That widens its addressable market beyond one test line; U.S. autoimmune disease affects about 50 million people, and TB reached 10.8 million cases in 2023.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutoimmune market\u003c\/td\u003e\n\u003ctd\u003e50 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTB cases\u003c\/td\u003e\n\u003ctd\u003e10.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMove\u003c\/td\u003e\n\u003ctd\u003eNew products, new buyers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233958732041,"sku":"adpt-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/adpt-ansoff-matrix.webp?v=1785709479","url":"https:\/\/dcfanalyst.com\/products\/adpt-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}